Bottom line. IQV’s 2Q26 report is the clearest evidence yet that the clinical-research demand recovery has moved beyond management commentary. Organic revenue grew 6%, R&DS organic growth reached 7%, and $3.15B of net bookings produced a 1.22x book-to-bill ratio. The catch is that stronger bookings matter more to 2027 than to 2026. At the midpoint, revised 2026 guidance implies $67M more 2H26 revenue than prior guidance did before the print. It also implies $4M less adjusted EBITDA and $0.02 less adjusted EPS. The quarter raises confidence in the recovery while shifting the debate to whether IQV can convert it profitably next year.
That distinction matters after the stock’s recent move. IQV rose 21.9% from the July 27 pre-print close through August 21, while consensus FY27 adjusted EPS and EBITDA increased just 1.9% and 1.2%, respectively. The market is no longer waiting for proof that demand has stabilized; it has started to capitalize a better 2027. That is not the same as saying the shares are expensive in absolute terms, but it does mean the burden of proof has changed. Further upside should depend less on another healthy bookings quarter and more on evidence that revenue conversion will carry operating leverage.
The recovery is becoming harder to dismiss
The 2Q26 print beat consensus in the places that mattered most. Revenue of $4.368B was $68M, or 1.6%, above consensus. Adjusted EBITDA of $994M beat by $29.5M, or 3.1%, and adjusted EPS of $3.15 beat by $0.12, or 4.0%. R&DS revenue was $65M/2.6% above consensus and accounted for approximately 96% of the companywide revenue beat; Commercial was only $3M/0.2% ahead. Book-to-bill reached 1.22x versus a 1.11x expectation. The one clear shortfall was backlog, which ended at $34.2B compared with the $34.5B expectation.
Bookings were more important for proving out the recovery than the quarterly beat. Net awards increased 19.3% year-over-year and 27% sequentially to the highest level since 2022. Management said the result was broadly based, with no oversized contract and normal cancellations, pass-through content and therapeutic mix. FSP awards remained at their normal low- to mid-double-digit share of total bookings, while full-service bookings were particularly strong. Last-twelve-month bookings rose for a fourth consecutive quarter to $11.25B, up 12.9%. RFP flow increased at a double-digit rate both sequentially and year-over-year, and decision timelines shortened.
The resulting backlog is one nit to pick against the strong bookings data. The $34.2B balance was flat sequentially and only $0.2B above recast year-end backlog, even as next-twelve-month backlog revenue rose 7.5% to $9.23B. IQV could adjust backlog by roughly 5% for inactive trials when it completes the review in the third quarter. Importantly, management said any adjustment would not affect historical results, guidance or next-twelve-month revenue from backlog. That frames it as backlog hygiene rather than an identified near-term earnings risk, but the tail remains unclean until the work is complete. Flat backlog does not negate stronger bookings, but it does prevent the quarter from proving a fully normalized book at the moment.
Sources: IQVIA; StreetAccount/FactSet; Graver Research analysis.
The guidance raise adds revenue without lifting implied 2H26 profit
The full-year outlook improved, but mainly at the top line. IQV raised the 2026 revenue midpoint by $125M to $17.375B, adjusted EBITDA by $25M to $4.025B, and adjusted EPS by $0.10 to $12.90. The new midpoints are $85M, $25M and $0.09 above pre-print consensus. Management’s bridge added roughly 100 bps of organic growth and 50 bps from acquisitions, partly offset by an FX tailwind that was 80 bps smaller than in prior guidance. 3Q26 revenue guidance was about $36M above consensus at the midpoint, while adjusted EBITDA and EPS were essentially in line. That guidance mostly de-risks growth. It does not imply incremental 2H26 earnings versus the prior framework.
The residual bridge makes that distinction clearer. Subtracting 1Q26 actuals and the prior 2Q26 midpoint from the former full-year midpoint yields $8.789B of implied 2H26 revenue, $2.103B of adjusted EBITDA and $6.87 of adjusted EPS. Subtracting 1Q26 and 2Q26 actuals from the updated midpoint produces $8.856B, $2.099B and $6.85. On that basis, the new framework contains $67M more 2H26 revenue but $4M less adjusted EBITDA and $0.02 less adjusted EPS.
Sources: IQVIA; Graver Research calculations.
The operating improvement was real, but earnings quality was mixed
Adjusted EBITDA margin expanded by about 10 bps to 22.76%. Management attributed roughly 90 bps of underlying margin expansion to operating and productivity programs, offset by approximately 80 bps of pass-through pressure; FX was negligible. Commercial and R&DS segment profit margins each improved by more than 40 bps. R&DS revenue grew 8.8% as reported but 6.7% excluding reimbursed expenses; acquisitions contributed about 2.5 points of company growth, and management expects the Charles River assets to add $75M-$80M to 2026 revenue at lower margins. Productivity is showing through, but mix still absorbed most of it. That’s good progress, but not yet a clean operating-leverage inflection.
Earnings quality was mixed rather than poor. Adjusted net income increased 8.4%, while adjusted EPS rose 12.1% as diluted shares declined 3.4%. GAAP operating income was flat, and selected stock-compensation and restructuring add-backs increased by a combined $60M. Restructuring is expected to continue through 2026 and into 2027, so it is not an isolated charge. The counterweight is cash: free cash flow increased 23.3% to $360M, and IQV repurchased $398M of shares. The operating story has cash support, but EPS growth was not entirely operational.
Outside evidence also supports demand recovery
The external evidence points in the same direction. MEDP’s net awards increased 28.2% to $795.7M, producing a 1.13x book-to-bill ratio, as RFP activity and opportunity quality improved. More than half of the sequential bookings gain, however, came from fewer cancellations. TMO reported strong authorizations at PPD and said awards typically take about six months to reach revenue. BioWorld provides a useful funding cross-check: 1H26 biopharma financing more than doubled to $60.14B, and the $67.65B raised through July was the fourth-highest total for the period. These signals support IQV’s demand story.
Peer anecdotes also show why bookings should not be confused with near-term profit. ICLR’s headline book-to-bill was 1.51x, but 1.20x on direct fees; revenue increased 1.2% while adjusted EBITDA fell 21.7%. FTRE posted quarterly and trailing ratios of 1.06x and 1.12x, yet revenue declined 4.5%.
IQV’s AI disclosures are also promising but incomplete: 294 agents span 90 use cases, with IQVIA solutions deployed in the workflows of 19 of the top 20 pharmaceutical companies and AI co-development work with four top-10 customers. IQV has not quantified the revenue, savings or returns. FTRE said AI is in most RFPs but is not the primary decision factor; ICLR expects discovery-led capacity effects to take years. AI may support IQV’s competitive position, but it is not yet an earnings claim.
The stock now requires profitable conversion
Expectations have moved much faster than estimates. IQV advanced from $213.22 on July 27 to $259.82 on August 21, a 21.9% gain. Consensus FY26 and FY27 adjusted EPS increased just 1.25% and 1.91%, while adjusted EBITDA rose 0.90% and 1.20%. The move should be seen more as a valuation rerating than as an earnings revision. Valuation does not support an obvious absolute-bear case: IQV now trades at 13.7x NTM EV/EBITDA and 19.0x NTM P/E, modestly below its 10-year medians. The issue is that more of the recovery is now reflected before the related profit has arrived.
Sources: Koyfin; Graver Research analysis.
The 2Q26 print established that IQV’s growth, bookings and external demand indicators are finally moving together. It did not settle the economics of 2027 conversion, resolve the backlog review, prove sustained margin leverage, or attach financial value to AI. The next evidence will be the 3Q26 print and backlog review, the December 2 Investor Day and, ultimately, the initial 2027 framework. Sustained book-to-bill above 1.0x, continued growth in next-twelve-month revenue from backlog and visible operating leverage would strengthen the interpretation. A bookings reversal, weaker conversion, a larger backlog adjustment or continued mix dilution would weaken it. The debate has moved from whether demand is stabilizing to whether IQV can turn it into profitable 2027 growth.